Angiotensin-converting-enzyme inhibitor–induced angioedema

descriptionPublicationkeyboard_double_arrow_right Article , Other literature type 16 May 2021 English Publisher:CMA Impact Inc.Journal:Canadian Medical Association Journal, volume 193, pages E735-E735 (issn: 0820-3946, eissn: 1488-2329,

Copyright policy )

Authors: Quickfall, Danica; Jakubovic, Baruch; Zipursky, Jonathan S.;

doi: 10.1503/cmaj.202308

pmid: 34001550

pmc: PMC8177945

Angiotensin-converting-enzyme inhibitor–induced angioedema

- Summary
- Subjects
- Metrics

Abstract

Angiotensin-converting-enzyme (ACE) inhibitors are responsible for 20%–40% of emergency department visits for angioedema.[1][1] The incidence of ACE inhibitor–induced angioedema is about 0.1%–0.7% in the first 5 years of treatment; symptoms occur within the first month in 10% of cases.[1][1]

Related Organizations

Keywords

Practice, Risk Factors, Humans, Angiotensin-Converting Enzyme Inhibitors, Angioedema

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	5
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average